newsfilter
← Latest News
PR Newswire·

Atrium Therapeutics Reports Second Quarter 2026 Financial Results

-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome ---- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb --SAN DIEGO, Aug. 13,